Sep 13, 2023 / 05:00PM GMT
Stephane Bancel - Moderna, Inc. - CEO & Director
Thank you for those joining us here, and thank you for those joining us online today. Before I start, let me just remind you that we'll be making forward-looking statements. And of course, investing in Moderna entails risk. Please look at these documents online, on the SEC website for your information. So 10-plus years ago, we started Moderna, believing that mRNA could be a very powerful molecule, an information molecule to make a new class of medicines.
And it was really exciting to us having spent years in pharma, having suffered from the small molecule failure rates, large molecule and the limitations. The notion that you can use an information molecule to make medicines was really, really exciting. And as you know, because many of you have seen these slides for now 10 years, what excited us is a few things. The first thing was the opportunity to have a very large product opportunity sets. The ability to go and do secreted proteins or combinations of secretive proteins. The ability to transmembrane proteins are very complex transmembrane
Moderna Inc R&D Day Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers